Clinical Trial Update: A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days [Phase 2]

View source ↗

Summary

A Phase 2 pharmacokinetic study of Bevirimat 100 mg tablets in HIV-1 infected individuals has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Bevirimat (bevirimat)

Snippet

Sponsor: Myrexis Inc. | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED